Quarter Comparison
Revenue
Operating Income
Free Cash Flow
Income Statement
Cash Flow Statement
Balance Sheet
Earnings Release
EX-99.1 2 tm2619129d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update Woburn, MA, June 29, 2026 – Replimune Group, Inc.
EX-99.1 2 tm2619129d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update Woburn, MA, June 29, 2026 – Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal fourth quarter and year ended March 31, 2026 and provided a business update. The Company recently announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma. The FDA considers this a complete, class 1 response with a goal date of August 2, 2026, and has notified the company to expect an advisory committee meeting in late July....
Source
Exhibit EX-99.1
0001104659-26-078511
Filed June 29, 2026 at 12:11 PM UTC. The figures above are from the audited statements, not from this release.